Wells Fargo Downgrades Nike to Equal Weight: GLP-1 Mega-Trend Threatens the Athletic Wear Giant

"Wells Fargo believes GLP-1 weight loss drugs are quietly rewiring consumer apparel demand. Nike, as the world's largest footwear maker, sits on the wrong side of that shift. The investor takeaway is that GLP-1 adoption is reshaping body silhouettes and consumer wardrobes, steering wallet share toward traditional apparel and away from the "wellness through exercise" narrative that powered athletic wear for over a decade."

"Wells Fargo's thesis is that Nike doesn't fit the firm's preference for clothing outperforming athletic apparel over the next few years. The argument is that GLP-1 adoption is reshaping body silhouettes and consumer wardrobes, steering wallet share toward traditional apparel and away from the "wellness through exercise" narrative that powered athletic wear for over a decade. Layered on top are company-specific concerns including a slower-than-expected global turnaround and international disruption likely to weigh on near-term results."

"Wells Fargo cited a slower-than-expected global turnaround, international disruption likely to weigh on near-term results, and over-saturation from excess competition. Nike is steering a "Win Now" restructuring, and the most recent quarter showed revenue of $11.28 billion (up 0.1% year over year) with diluted EPS of $0.35 beating the $0.28 estimate. Yet pressure points remain visible, including net income down 35% year over year and gross margin compressed 130 basis points to 40%."

"Nike's market cap stands at $52.92 billion, with shares fetching a forward P/E ratio of 22x. Pressure points remain visible as Greater China declined 10% on a currency-neutral basis while Converse dropped 35%. Premium running brands like On and Hoka have eaten into Nike's core, and the GLP-1 angle suggests the total addressable market for athletic apparel may be changing."

Nike was downgraded to Equal Weight from Overweight, with a price target reduced to $45 from $55. The downgrade reflects a view that GLP-1 weight loss drugs are changing body silhouettes and consumer wardrobes, redirecting spending toward traditional apparel and away from athletic wear. Nike is also facing slower-than-expected global turnaround, likely international disruption affecting near-term results, and excess competition driving oversaturation. Financially, Nike reported $11.28 billion in revenue with diluted EPS of $0.35, but net income fell 35% year over year and gross margin declined 130 basis points to 40%. Greater China declined 10% on a currency-neutral basis, and Converse fell 35%.

Read at 24/7 Wall St.